Biotech Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026 November 15, 2026
Biotech IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors November 15, 2026
Biotech Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update November 14, 2026
Biotech TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update November 13, 2026
Biotech MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update November 13, 2026
Biotech Lilly breaks ground in Pennsylvania’s Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020 November 13, 2026
Biotech Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results November 13, 2026